Bayer issues muted 2011 outlook on generic rivals
LEVERKUSEN, Germany Feb 28 (Reuters) - Germany's largest drugmaker, Bayer (BAYGn.DE), issued two-year targets for adjusted core earnings that fell slightly short of analysts expectations as generic competition weighs on its best-selling pharmaceuticals.
The group said on Monday it expects earnings before interest, taxes, depreciation and amortisation (EBITDA) to rise "toward" 7.5 billion euros ($10.32 billion) this year and to reach about 8 billion euros in 2012.
Analysts had factored in figures of 7.8 billion and 8.5 billion for 2011 and 2012, respectively. [ID:nLDE71M0W3]
Growth this year will likely driven by a recovery from pesticides and chemicals, while a boost from a new drug will not kick in before next year.
The drugs to chemicals group is pinning hopes on its anti-blood-clotting pill Xarelto which in November was shown to have mass-market potential in a late-stage trial. [ID:nN15246556]
Bayer reiterated on Monday it expects more than 2 billion euros in annual sales from the drug.
(Reporting by Ludwig Burger)
- WTO overcomes last minute hitch to reach its first global trade deal
- Colorado baker discriminated by denying gay couple wedding cake: judge
- Flights delayed as air pollution hits record in Shanghai
- U.S. freeze shows no sign of weekend melt after deadly storm
- Australia foreign minister downplays China air defense zone tension in visit